Differences in Cognitive Outcomes after ECT Depending on BDNF and COMT Polymorphisms

Journal of ECT

Volumn 32, Issue 4, 2016, Pages 243-250

  Bennett, Daniel Mark ^a   Currie, James ^a   Fernie, Gordon ^a   Perrin, Jennifer S ^a   Reid, Ian C ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

BDNF; COMT; ECT; Electroconvulsive therapy

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; COMT PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COGNITION ASSESSMENT; DEPRESSION; ELECTROCONVULSIVE THERAPY; FEMALE; GENOTYPING TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; SCOTLAND; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; COGNITION; DEPRESSIVE DISORDER, MAJOR; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOL O-METHYLTRANSFERASE; COGNITION; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84969165057     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0000000000000325     Document Type: Article

References (38)

1. Taylor SM. Electroconvulsive therapy, brain-derived neurotrophic factor, and possible neurorestorative benefit of the clinical application of electroconvulsive therapy. J ECT. 2008;24:160-165.
2. Dincheva I, Glatt CE, Lee FS. Impact of the BDNF Val66Met polymorphism on cognition: impact for behavioral genetics. Neuroscientist. 2012;18:439-451.
3. Pezawas L, Verchinski BA, Mattay VS, et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci. 2004;24:10099-10102.
4. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257-269.
5. Hariri AR, Goldberg TE, Mattay VS, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci. 2003; 23:6690-6694.
6. Szeszko PR, Lipsky R, Mentschel C, et al. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. J Mol Psychiatry. 2005;10:631-636.
7. Schofield PR, Williams LM, Paul RH, et al. Disturbances in selective information processing associated with the BDNF val66met polymorphism: evidence fromcognition, the P300 and fronto-hippocampal systems. Biol Psychol. 2009;80:176-188.
8. Ho B, Milev P, O'Leary DS, et al. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry. 2006;63:731-740.
9. Falconer D, Cleland J, Fielding S, et al. Using the Cambridge Neuropsychological Test Automated Battery (CANTAB) to assess the cognitive impact of electroconvulsive therapy on visual and visuospatial memory. Psychol Med. 2010;40:1017-1025.
10. Fernie G, Bennett DM, Currie J, et al. Detecting objective and subjective cognitive effects of electroconvulsive therapy: intensity, duration and test utility in a large clinical sample. Psychol Med. 2014;44: 2985-2994.
11. Owen AM, Sahakian BJ, Semple J, et al. Visuo-spatial short-term recognitionmemory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia. 1995;33:1-24.
12. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:261-265.
13. Gonul AS, Akdeniz F, Taneli F, et al. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci. 2005;255:381-386.
14. Karege F, Perret G, Bondolfi G, et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002;109:143-148.
15. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54:70-75.
16. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-Analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 2008; 11:1169-1180.
17. Zou Y, Ye D, Feng X, et al. Meta-Analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol. 2010;20:535-544.
18. Verhagen M, van der Meij A, van Deurzen P, et al. Meta-Analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry. 2010;15:260-271.
19. Gyekis JP, YuW, Dong S, et al. No association of genetic variants in BDNF withmajor depression: a meta-And gene-based analysis. Am JMed Genet B Neuropsychiatr Genet. 2012;162B:61-70.
20. Hu Y, Yu X, Yang F, et al. The level of serum brain-derived neurotrophic factor is associated with the therapeutic efficacy of modified electroconvulsive therapy in Chinese patients with depression. J ECT. 2010;26:121-125.
21. Haghighi M, Salehi I, Erfani P, et al. Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only. J Psychiatr Res. 2013; 47:908-915.
22. Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-Analysis. Biol Psychiatry. 2010;68:568-577.
23. Burdick KE, Funke B, Goldberg JF, et al. COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. Bipolar Disord. 2007;9:370-376.
24. Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004;75: 807-821.
25. Fiocco AJ, Lindquist K, Ferrell R, et al. COMT genotype and cognitive function. An 8-year longitudinal study in white and black elders. Neurology. 2010;74:1296-1302.
26. EganMF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A. 2001;98:6917-6922.
27. Mata I, Arranz MJ, Staddon S, et al. The high-Activity Val allele of the catechol-o-methyltransferase gene predicts greater cognitive deterioration in patients with psychosis. Psychiatr Genet. 2006;16:213-216.
28. Funke B, Malhotra AK, Finn CT, et al. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav Brain Funct. 2005;1:19.
29. Massat I, Souery D, Del-Favero J, et al. Association between COMT (Val158Met) functional polymorphism and earlyu onset in patients with major depressive disorder in a European multicenter genetic association study. Mol Psychiatry. 2005;10:598-605.
30. Serretti A, Rotondo A, Lorenzi C, et al. Catechol-O-methyltransferase gene variants in mood disorders in the Italian population. Psychiatr Genet. 2006;16:181-182.
31. Anttila S, Huuhka K, Huuhka M, et al. Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy. Pharmacogenomics J. 2008;8:113-116.
32. Domschke K, Zavorotnyy M, Diemer J, et al. COMT val158met influence on electroconvulsive therapy response in major depression. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:286-290.
33. Bousman CA, Katalinic N, Martin DM, et al. Effects of COMT, DRD2, BDNF, and APOE genotypic variation on treatment efficacy and cognitive side effects of electroconvulsive therapy. J ECT. 2015;31:129-135.
34. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
35. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
36. Nelson HE. National Adult Reading Test (NART):Test Manual. Windsor: NFER-NELSON; 1982.
37. Bennett DM, Perrin JS, Currie J, et al. A comparison of ECT dosing methods using a clinical sample. J Affect Disord. 2012;141:222-226.
38. Stienart P, Vansteelandt K, Demyttenaere K, et al. Ultra-brief pulse ECT in bipolar and unipolar depressive disorder: differences in speed of response. Bipolar Disord. 2009;11:418-424.